The application, titled ‘Dynamic spine stabilization device with travel-limiting functionality’ (US application No. 11/189,512), describes the use of a travel limiting feature as part of a flexible spinal stabilization device.

Bruce Robie, vice president of R&D at Applied Spine, said: “To be clinically useful, a dynamic stabilization device needs to allow the spine to move, but not move excessively. This Notice of Allowance protects a class of devices that enable motion, like our Stabilimax device, and include structure to protect against the device moving excessively.”

Craig Corrance, president and CEO of Applied Spine, said: “This Notice demonstrates further evidence of our ever maturing Intellectual Property. The company constantly manages its IP portfolio in order to protect and differentiate our Stabilimax platform while also working closely with its IP Counsel to ensure continuation of patent grants, both near term and in the years ahead.”